Expanded coverage for weight loss drugs could cost Medicare billions

There's an increasing buzz among patients for GLP-1 weight loss drugs, such as Novo Nordisk's Ozempic and Wegovy, but if patient demand continues to grow and Medicare expanded its coverage in response, it could cost the federal program between $13.6 and $26.8 billion annually.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive